Versant Ventures, a global healthcare venture capital firm, announced promotions and an addition to its investment team, as well as appointments at its discovery engines in Toronto and New York City.
In details, Versant promoted Jerel Davis to Managing Director to continue to build the biotech portfolio and presence in Canada and North America, and Carlo Rizzuto to Partner to anchor investment operations in the Northeast. In addition, the firm hired Luca Santarelli as Venture Partner, a pharmaceutical executive who will join the investment team in Basel, Switzerland.
In addition, the firm’s Toronto-based discovery engine Blueline Bioscience appointed Mary Haak-Frendscho as CEO to lead company creation and incubation efforts in partnership with academics and entrepreneurs in Ontario and throughout Canada.
Finally, New York City-based Highline Therapeutics added CSO Joe Vacca and Operating Partner Paul Sekhri.